The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis
Abstract Background It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, the difference of effectiveness in reducing HCC occurrence between tenofovir...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-05-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12885-019-5735-9 |
| _version_ | 1818109453714587648 |
|---|---|
| author | Zeyu Zhang Yufan Zhou Jiajin Yang Kuan Hu Yun Huang |
| author_facet | Zeyu Zhang Yufan Zhou Jiajin Yang Kuan Hu Yun Huang |
| author_sort | Zeyu Zhang |
| collection | DOAJ |
| description | Abstract Background It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir (ETV), two first-line NAs drugs, is still little known. This meta analysis aims to assess the efficacy in reducing incidence of HCC comparing tenofovir monotherapy with entecavir monotherapy among chronic hepatitis B (CHB) patients by analyzing their long-term clinical outcomes. Methods Databases including PubMed, Embase, Cochrane Central Register of Controlled Trial, and ISI Web of Science were fully investigated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. For the included articles, two of the authors independently extracted and confirmed relevant data. Review Manager software (RevMan 5.3) was using for meta analysis. Results Seven articles with 3698 patients were finally included in this research, 1574 in tenofovir group and 2124 in entecavir group. For meta analysis, the incidence of HCC was significantly lower among the tenofovir group than entecavir group [rate ratio (95% CI) of 0.66 (0.49, 0.89), P = 0.008], while there was no statistical significance in incidence of death or transplantation [rate ratio (95% CI) of 0.78 (0.55, 1.13), P = 0.19], encephalopathy [risk ratio (95% CI) of 0.72 (0.45, 1.13), P = 0.15] or variceal bleeding [risk ratio (95% CI) of 0.71 (0.34, 1.50), P = 0.37] between the two groups. Conclusion There is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients. However before applying, randomized controlled trial and large prospective cohort study should be performed in the future. |
| first_indexed | 2024-12-11T02:31:30Z |
| format | Article |
| id | doaj.art-e814238e469943dea3f4004ade8900e2 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-12-11T02:31:30Z |
| publishDate | 2019-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-e814238e469943dea3f4004ade8900e22022-12-22T01:23:49ZengBMCBMC Cancer1471-24072019-05-011911910.1186/s12885-019-5735-9The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysisZeyu Zhang0Yufan Zhou1Jiajin Yang2Kuan Hu3Yun Huang4Department of Hepatobiliary Surgery, Xiangya Hospital, Central South UniversityDepartment of Hepatobiliary Surgery, Xiangya Hospital, Central South UniversityDepartment of Hepatobiliary Surgery, Xiangya Hospital, Central South UniversityDepartment of Hepatobiliary Surgery, Xiangya Hospital, Central South UniversityDepartment of Hepatobiliary Surgery, Xiangya Hospital, Central South UniversityAbstract Background It has been proved that nucleos(t) ide analogues (NAs) therapy could improve underlying liver disease and reduce the incidence of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). However, the difference of effectiveness in reducing HCC occurrence between tenofovir (TDF) and enticavir (ETV), two first-line NAs drugs, is still little known. This meta analysis aims to assess the efficacy in reducing incidence of HCC comparing tenofovir monotherapy with entecavir monotherapy among chronic hepatitis B (CHB) patients by analyzing their long-term clinical outcomes. Methods Databases including PubMed, Embase, Cochrane Central Register of Controlled Trial, and ISI Web of Science were fully investigated according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. For the included articles, two of the authors independently extracted and confirmed relevant data. Review Manager software (RevMan 5.3) was using for meta analysis. Results Seven articles with 3698 patients were finally included in this research, 1574 in tenofovir group and 2124 in entecavir group. For meta analysis, the incidence of HCC was significantly lower among the tenofovir group than entecavir group [rate ratio (95% CI) of 0.66 (0.49, 0.89), P = 0.008], while there was no statistical significance in incidence of death or transplantation [rate ratio (95% CI) of 0.78 (0.55, 1.13), P = 0.19], encephalopathy [risk ratio (95% CI) of 0.72 (0.45, 1.13), P = 0.15] or variceal bleeding [risk ratio (95% CI) of 0.71 (0.34, 1.50), P = 0.37] between the two groups. Conclusion There is a better effect of tenofovir in reducing HCC incidence than entecavir, which indicates tenofovir should be used more widely while treating chronic hepatitis B patients. However before applying, randomized controlled trial and large prospective cohort study should be performed in the future.http://link.springer.com/article/10.1186/s12885-019-5735-9EntecavirTenofovirChronic hepatitis BHepatocellular carcinomaMeta-analysis |
| spellingShingle | Zeyu Zhang Yufan Zhou Jiajin Yang Kuan Hu Yun Huang The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis BMC Cancer Entecavir Tenofovir Chronic hepatitis B Hepatocellular carcinoma Meta-analysis |
| title | The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis |
| title_full | The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis |
| title_fullStr | The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis |
| title_full_unstemmed | The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis |
| title_short | The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis |
| title_sort | effectiveness of tdf versus etv on incidence of hcc in chb patients a meta analysis |
| topic | Entecavir Tenofovir Chronic hepatitis B Hepatocellular carcinoma Meta-analysis |
| url | http://link.springer.com/article/10.1186/s12885-019-5735-9 |
| work_keys_str_mv | AT zeyuzhang theeffectivenessoftdfversusetvonincidenceofhccinchbpatientsametaanalysis AT yufanzhou theeffectivenessoftdfversusetvonincidenceofhccinchbpatientsametaanalysis AT jiajinyang theeffectivenessoftdfversusetvonincidenceofhccinchbpatientsametaanalysis AT kuanhu theeffectivenessoftdfversusetvonincidenceofhccinchbpatientsametaanalysis AT yunhuang theeffectivenessoftdfversusetvonincidenceofhccinchbpatientsametaanalysis AT zeyuzhang effectivenessoftdfversusetvonincidenceofhccinchbpatientsametaanalysis AT yufanzhou effectivenessoftdfversusetvonincidenceofhccinchbpatientsametaanalysis AT jiajinyang effectivenessoftdfversusetvonincidenceofhccinchbpatientsametaanalysis AT kuanhu effectivenessoftdfversusetvonincidenceofhccinchbpatientsametaanalysis AT yunhuang effectivenessoftdfversusetvonincidenceofhccinchbpatientsametaanalysis |